Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance

DOI record: { "DOI": "10.1007/s43440-022-00408-6", "ISSN": [ "1734-1140", "2299-5684" ], "URL": "http://dx.doi.org/10.1007/s43440-022-00408-6", "abstract": "<jats:title>Abstract</jats:title><jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>Among 11,822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 31 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisons.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age.</jats:p>\n </jats:sec>", "alternative-id": [ "408" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "28 June 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Revised", "name": "revised", "order": 2, "value": "12 August 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 3, "value": "17 August 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 4, "value": "24 August 2022" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Robert Flisiak and Jerzy Jaroszewicz reports grants and personal fees from MSD, Gilead, and Roche; Dorota Zarębska-Michaluk reports personal fees from MSD and Gilead; Justyna Kowalska reports grants and personal fees from MSD, Gilead, Janssen Cilag, GSK/ViiV and Roche; Anna Moniuszko-Malinowska reports personal fee from DiaSorin; Regina Podlasin reports personal fees from Gilead; Magdalena Rogalska, Justyna Anna Kryńska, Ewa Dutkiewicz, Krystyna Dobrowolska, Marta Rorat, Olga Tronina, Piotr Rzymski report no financial interests in relation to the work described." } ], "author": [ { "ORCID": "http://orcid.org/0000-0003-3394-1635", "affiliation": [], "authenticated-orcid": false, "family": "Flisiak", "given": "Robert", "sequence": "first" }, { "affiliation": [], "family": "Zarębska-Michaluk", "given": "Dorota", "sequence": "additional" }, { "affiliation": [], "family": "Rogalska", "given": "Magdalena", "sequence": "additional" }, { "affiliation": [], "family": "Kryńska", "given": "Justyna Anna", "sequence": "additional" }, { "affiliation": [], "family": "Kowalska", "given": "Justyna", "sequence": "additional" }, { "affiliation": [], "family": "Dutkiewicz", "given": "Ewa", "sequence": "additional" }, { "affiliation": [], "family": "Dobrowolska", "given": "Krystyna", "sequence": "additional" }, { "affiliation": [], "family": "Jaroszewicz", "given": "Jerzy", "sequence": "additional" }, { "affiliation": [], "family": "Moniuszko-Malinowska", "given": "Anna", "sequence": "additional" }, { "affiliation": [], "family": "Rorat", "given": "Marta", "sequence": "additional" }, { "affiliation": [], "family": "Podlasin", "given": "Regina", "sequence": "additional" }, { "affiliation": [], "family": "Tronina", "given": "Olga", "sequence": "additional" }, { "affiliation": [], "family": "Rzymski", "given": "Piotr", "sequence": "additional" } ], "container-title": "Pharmacological Reports", "container-title-short": "Pharmacol. Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2022, 8, 24 ] ], "date-time": "2022-08-24T13:02:15Z", "timestamp": 1661346135000 }, "deposited": { "date-parts": [ [ 2022, 8, 24 ] ], "date-time": "2022-08-24T13:03:53Z", "timestamp": 1661346233000 }, "funder": [ { "name": "Polskie Towarzystwo Epidemiologów i Lekarzy Chorób Zakaźnych" } ], "indexed": { "date-parts": [ [ 2022, 8, 25 ] ], "date-time": "2022-08-25T04:09:56Z", "timestamp": 1661400596990 }, "is-referenced-by-count": 1, "issued": { "date-parts": [ [ 2022, 8, 24 ] ] }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 8, 24 ] ], "date-time": "2022-08-24T00:00:00Z", "timestamp": 1661299200000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 8, 24 ] ], "date-time": "2022-08-24T00:00:00Z", "timestamp": 1661299200000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s43440-022-00408-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s43440-022-00408-6/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s43440-022-00408-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2022, 8, 24 ] ] }, "published-online": { "date-parts": [ [ 2022, 8, 24 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1016/j.isci.2022.104076", "author": "A-L Mader", "doi-asserted-by": "publisher", "journal-title": "IScience", "key": "408_CR1", "unstructured": "Mader A-L, Tydykov L, Glück V, Bertok M, Weidlich T, Gottwald C, et al. Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. IScience. 2022;25: 104076.", "volume": "25", "year": "2022" }, { "DOI": "10.1016/j.antiviral.2022.105252", "author": "L Vangeel", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res", "key": "408_CR2", "unstructured": "Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198: 105252.", "volume": "198", "year": "2022" }, { "DOI": "10.1007/s43440-022-00388-7", "doi-asserted-by": "publisher", "key": "408_CR3", "unstructured": "Rahmah L, Abarikwu SO, Arero AG, Jibril AT, Fal A, Flisiak R, et al. Oral antiviral treatments for COVID-19: opportunities and challenges. Rep: Pharmacol; 2022. https://doi.org/10.1007/s43440-022-00388-7." }, { "DOI": "10.1016/j.coviro.2021.06.003", "author": "GR Painter", "doi-asserted-by": "publisher", "first-page": "17", "journal-title": "Curr Opin Virol", "key": "408_CR4", "unstructured": "Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021;50:17–22.", "volume": "50", "year": "2021" }, { "DOI": "10.1038/s41586-021-03312-w", "author": "A Wahl", "doi-asserted-by": "publisher", "first-page": "451", "journal-title": "Nature", "key": "408_CR5", "unstructured": "Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH 3rd, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–7.", "volume": "591", "year": "2021" }, { "key": "408_CR6", "unstructured": "Kumarasamy N, Jindal, A, Saha, B, Singh VB, Rodduturi NCR, Sinha S, Sriramadasu SC. Phase III trial of molnupiravir in adults with mild SARS-cov2 infection in India. In: CROI Virtual Conference, Denver 2022, abstract #101" }, { "DOI": "10.1016/j.jbc.2021.100770", "author": "CJ Gordon", "doi-asserted-by": "publisher", "journal-title": "J Biol Chem", "key": "408_CR7", "unstructured": "Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297: 100770.", "volume": "297", "year": "2021" }, { "DOI": "10.1056/NEJMoa2116044", "author": "BA Jayk", "doi-asserted-by": "publisher", "first-page": "509", "journal-title": "N Engl J Med", "key": "408_CR8", "unstructured": "Jayk BA, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–20.", "volume": "386", "year": "2022" }, { "DOI": "10.1056/evidoa2100044", "author": "JR Arribas", "doi-asserted-by": "publisher", "journal-title": "NEJM Evid", "key": "408_CR9", "unstructured": "Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, et al. Randomized trial of molnupiravir or placebo in patients hospitalized with covid-19. NEJM Evid. 2022. https://doi.org/10.1056/evidoa2100044.", "year": "2022" }, { "DOI": "10.20452/pamw.16140", "author": "R Flisiak", "doi-asserted-by": "publisher", "first-page": "487", "journal-title": "Pol Arch Intern Med", "key": "408_CR10", "unstructured": "Flisiak R, Horban A, Jaroszewicz J, Kozielewicz D, Mastalerz-Migas A, Owczuk R, et al. Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. Pol Arch Intern Med. 2021;131:487–96. https://doi.org/10.20452/pamw.16140.", "volume": "131", "year": "2021" }, { "DOI": "10.20452/pamw.16230", "author": "R Flisiak", "doi-asserted-by": "publisher", "journal-title": "Pol Arch Intern Med", "key": "408_CR11", "unstructured": "Flisiak R, Horban A, Jaroszewicz J, Kozielewicz D, Mastalerz-Migas A, Owczuk R, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. Pol Arch Intern Med. 2022. https://doi.org/10.20452/pamw.16230.", "year": "2022" }, { "key": "408_CR12", "unstructured": "MI2DataLab. Monitor of SARS-CoV-2. 2022. https://monitor.crs19.pl/2022-03-31/poland/?lang=en. Accessed June 23 2022." }, { "author": "R Flisiak", "first-page": "103", "journal-title": "Pol Arch Intern Med", "key": "408_CR13", "unstructured": "Flisiak R, Zarębska-Michaluk D, Berkan-Kawińska A, Tudrujek-Zdunek M, Rogalska M, Piekarska A, et al. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Pol Arch Intern Med. 2021;131:103–10.", "volume": "131", "year": "2021" }, { "DOI": "10.2147/JIR.S322645", "author": "D Zarębska-Michaluk", "doi-asserted-by": "publisher", "first-page": "3359", "journal-title": "J Inflamm Res", "key": "408_CR14", "unstructured": "Zarębska-Michaluk D, Jaroszewicz J, Rogalska M, Martonik D, Pabjan P, Berkan-Kawińska A, et al. Effectiveness of tocilizumab with and without dexamethasone in patients with severe COVID-19: a retrospective study. J Inflamm Res. 2021;14:3359–66.", "volume": "14", "year": "2021" }, { "DOI": "10.1101/2022.05.19.22275291", "author": "CKH Wong", "doi-asserted-by": "publisher", "journal-title": "BioRxiv", "key": "408_CR15", "unstructured": "Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study. BioRxiv. 2022. https://doi.org/10.1101/2022.05.19.22275291.", "year": "2022" } ], "reference-count": 15, "references-count": 15, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s43440-022-00408-6" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology", "General Medicine" ], "subtitle": [], "title": "Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }